MIRA Pharmaceuticals (MIRA) announced that its novel oral ketamine analog, Ketamir-2, has shown greater pain relief compared to FDA-approved ...
MIRA READ THE FULL MIRA RESEARCH REPORT MIRA Pharmaceuticals (NASDAQ:MIRA) is a preclinical-stage pharmaceutical company focused on the development and commercialization of a new molecular synthetic ...
Non-Habit Forming: Unlike Pregabalin, Ketamir-2 carries no known risk of dependence, making it safer for long-term use. Fewer ...
Benzinga (Video) on MSN19d
Small Changes… Big Effects! Breakthrough Therapies Are The Name Of The Game For This BiopharmaErez Aminov, CEO & Chairman of the Board, and Dr. Itzchak Angel, Chief Scientific Advisor for MIRA Pharmaceuticals MIRA, were ...
BRIDGEWATER, NJ and LONDON, UK / ACCESSWIRE / September 30, 2024 / Tharimmune, Inc. (NASDAQ:THAR) ("Tharimmune"), a clinical-stage biotechnology company developing a portfolio of therapeutic ...
MONTREAL, QC / ACCESSWIRE / September 27, 2024 / KAN Football Club is proud to announce the release of a new episode of its podcast, featuring an exclusive interview with Nacho Piatti, former star ...
MIRA shares surge 10.3% after new preclinical data shows Ketamir-2 achieves 100% reversal of neuropathic pain. Ketamir-2 presentation set for October's Pain Therapeutics Summit, highlighting its ...
IRVINE, CA / ACCESSWIRE / September 26, 2024 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of venous disease ...
SOURCE: 01 Communique Laboratory, Inc.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback